Brazil/South Korea Move To ICH Driving Seat Raises Global Harmonization Expectations
Executive Summary
Brazil and South Korea have been accepted as new regulatory members of the International Council for Harmonisation. This has raised expectations that ICH guidelines will gain full acceptance in both countries, making it easier for the global innovative pharmaceutical industry to market their products there.
You may also be interested in...
Brazil's Backlog Is Nearly Clear, But Convergence Still A Work In Progress
Drug application backlog has been distraction for agency and prevents focus on other projects, says ANVISA General Manager of Drugs Raphael Sanches Pereira.
Brazil Revises Stability Study Standards To Bring Companies More Certainty
Brazil’s medicines regulator ANVISA intends to update its criteria for stability studies for medicines so as to bring them into line with ICH guidelines and give drug developers more certainty.
ICH Reformed At Last, Expects More Drug Regulators To Join In
The International Conference of Harmonisation has at last finalized its organizational reforms that are expected to encourage the group's expansion beyond its current membership of regulators from five regions (Canada, the EU, Japan, Switzerland and the US) and three research-based pharmaceutical industry associations (from the EU, Japan and the US)1.